Navigation Links
Biodel Reports Second Quarter Fiscal Year 2011 Financial Results
Date:5/5/2011

DANBURY, Conn., May 5, 2011 /PRNewswire/ -- Biodel Inc. (Nasdaq: BIOD) today reported financial results for the quarter ended March 31, 2011.

Second Quarter Fiscal Year 2011 Financial Results

Biodel reported a net loss for the three months ended March 31, 2011 of $5.4 million, or $0.21 per share, compared to a net loss of $10.4 million, or $0.44 per share, for the same period in the prior year.

Research and development expenses were $2.9 million for the three months ended March 31, 2011, compared to $7.0 million for the same period in the prior year.  The decrease of $4.1 million in expenses was primarily attributed to non-recurring events that occurred in the previous fiscal year including the conclusion of the Linjeta™ Phase 3 extension trials in February 2010 at a cost of $2.1 million; recombinant human insulin purchased at a cost of $1 million; professional fees of $0.7 million related to the 120 day safety report filing of Linjeta™ and follow-on questions from the FDA, and pen development costs of $0.4 million.

General and administrative expenses totaled $2.3 million for the three months ended March 31, 2011, compared to $3.4 million for the same period in the prior year.  The decrease in general and administrative expenses was attributable to a decrease in personnel costs of $0.7 million as a result of lower headcount from 2010, and savings of $0.4 million in professional fees due to cost cutting measures.

Expenses for the three months ended March 31, 2011 and 2010 included $2.6 million in stock-based compensation expense related to options granted to employees and non-employee directors.  

Biodel did not recognize any revenue during the three months ended March 31, 2011 or 2010.

At March 31, 2011, Biodel had cash and cash equivalents of $17.6 million and 26.5 million shares outstanding.  


'/>"/>
SOURCE Biodel Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Biodel to Report Second Quarter Fiscal Year 2011 Financial Results on May 5, 2011
2. BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
3. Biodel Announces Appointment of Dr. Brian J.G. Pereira as Board Chairman; Dr. Charles A. Sanders to Remain on Board
4. Biodel Announces Accelerated Development Plan for Ultra-Rapid-Acting Insulins: Initiate Phase 2 in 2011; Phase 3 Pivotal Trials in 2012
5. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
6. Biodel Inc. to Present at the Roth 23rd Annual OC Growth Stock Conference on March 16, 2011
7. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
8. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
9. Biodel Reports First Quarter Fiscal Year 2011 Financial Results
10. Biodel to Report First Quarter Fiscal Year 2011 Financial Results on February 3, 2011
11. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... PITTSBURGH , Aug. 28, 2015 ... announced that its shareholders have approved Mylan,s proposed ... ; TASE) and the related issuance of Mylan ... general meeting of shareholders held today. The transaction ... the extraordinary general meeting. In addition, the transaction ...
(Date:8/28/2015)... and LONDON , August 28, ... approach seamlessly connects people, ... improving outcomes and the cost ... PHG AEX: PHIA) today announced its presence at  ESC ... cardiology solutions, including Heart Model A.I. , EchoNavigator and IntelliSpace ...
(Date:8/27/2015)... , Aug. 27, 2015 DURECT Corporation (Nasdaq: ... to present at three upcoming healthcare conferences.  ... CEO, will present at the Rodman & Renshaw Investment ... time. The conference is being held at the St. ... . A live audio webcast of the presentation will ...
Breaking Medicine Technology:Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 2Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 3Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 4Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 5Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 6Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 7Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 8Mylan Shareholders Overwhelmingly Approve Proposed Acquisition of Perrigo 9Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 2Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 3Philips Showcases New Integrated Cardiology Solutions to Advance Minimally Invasive Procedures at ESC Congress 2015 4DURECT to Participate in Upcoming Healthcare Conferences 2
... SAN DIEGO--(BUSINESS WIRE)--Mar 29, 2007 - ACADIA ... technology to fuel drug discovery and clinical,development ... today announced that the company will present ... held from,March 28 through April 1, 2007, ...
... 29, 2007 /PRNewswire-FirstCall/ -- Baxter,International Inc. today announced ... H5N1 influenza vaccine and,plans to initiate a Phase ... to confirm the study results. , The Phase ... highly immunogenic at low doses, and induces substantial,levels ...
Cached Medicine Technology:ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 2ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 3ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 4ACADIA Pharmaceuticals' Schizophrenia Programs to Be Presented at,the 2007 International Congress on Schizophrenia Research 5Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 2Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 3Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 4Baxter Announces Final Phase I/II Data and Initiation of Phase III,Clinical Trial for Candidate Pandemic H5N1 Influenza Vaccine 5
(Date:8/30/2015)... CA (PRWEB) , ... August 30, 2015 , ... ... Focused Ultrasound (HIFU) medical devices for the treatment of prostate cancer, has announced ... introduced this summer at the treatment center in Puerto Vallarta, Mexico. , The ...
(Date:8/29/2015)... ... August 29, 2015 , ... ... two inventors from Miller Place, N.Y. "I specialize in manual therapy, and my ... addition, it can be used for additional muscle dysfunction throughout the body." , ...
(Date:8/29/2015)... ... ... Next weekend is Labor Day weekend, the last bash of the season ... year). For IT security personnel, it should also mark the perfect time to make ... than a simple headache. , Joe Caruso, founder and CEO-CTO of Global Digital ...
(Date:8/29/2015)... ... August 29, 2015 , ... Vascular Health ... and sell Arterosil and Arterosil HP, and that all claims and counterclaims have ... Health Sciences, LLC (VHS) in the United States District Court for the Southern ...
(Date:8/28/2015)... ... 28, 2015 , ... The Kentucky State Department of Workforce Investment Commissioner Beth ... are applying for, they are unable to pass the initial drug test and therefore ... policies in order to be able to hire long-term, skilled talent. (1) Will Wesch, ...
Breaking Medicine News(10 mins):Health News:Image Fusion Technology Combines MRI and Ultrasound Images to Treat Prostate Cancer 2Health News:Inventors and InventHelp Clients Develops Tension Reliever (LGI-1951) 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 2Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 3Health News:Business Cyber Security – Come Out of the Summer with a Clean Slate 4Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 2Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 3Health News:Hiring Obstacles: Drug Abuse a Problem for Workforce 4
... police officers, school leaders, in addition to the East ... break out. // Officials belonging to these departments are ... department everywhere has to be at the forefront while ... epidemics in the past which had devastated whole civilizations. ...
... of Biological Sciences, University of Southampton have reported that ... to inhibit the growth of Influenza A virus. In ... copper reduced the Plaque Forming Units (PFU) of Influenza ... there is an increased world wide threat of bird ...
... suffer from asthmatic symptoms, carrying a girl foetus are more ... a male foetus, // according to a recent study. Michael ... studied 702 pregnant women throughout southern New England who were ... selected points in pregnancy. ,Lung function and ...
... to India for the sake of low priced cosmetic ... waistline, rhinoplasty, and breast improvements are very expensive. // ... UK every year. ,Recent figures released ... that breast enlargement topped the list of cosmetic operations ...
... Lords committee report has revealed that about 90% of ... not actually been tested on children. Drugs like thyrozine, ... to children in spite of them not being licensed ... given to children have not undergone proper tests with ...
... Researchers belonging to the Oxford University in England have revealed ... their own treatment and taught to scale down the risk ... be avoided. Those patients who change the doses of warfarin, ... blood run the risk of dying within two years, which ...
Cached Medicine News:Health News:More People Come To India For Cosmetic Surgery 2
... pressure intravascular catheters provide a simple, ... measuring pressures in the heart or ... catheters are ideal for high fidelity ... size from 2 to 7 French ...
... Mikro-Tip pressure intravascular catheters provide a ... of measuring pressures in the heart ... Mikro-Tip catheters are ideal for high ... in size from 2 to 7 ...
... dual pressure sensor catheters incorporate ... slow-speed injection/guide wire, or high-speed ... for high-speed injection has two ... and an open-end pigtail extension ...
... dBC is a flat detector biplane ... ideal for cardiological diagnostics and intervention. ... you to optimally adapt the system ... and electrophysiological applications with tableside operation. ...
Medicine Products: